Chemours (NYSE:CC) CFO Shane Hostetter Buys 3,350 Shares

Key Points

• Chemours CFO Shane Hostetter purchased 3,350 shares at an average price of $14.94, investing approximately $50,049 and increasing his holdings by 3.37% to 102,698 shares.
• Chemours recently reported quarterly adjusted EPS of $0.42, below the $0.49 analyst consensus, while revenue of $1.59 billion also missed estimates and declined 1.5% year over year.
• Shares traded near $14.52, while analysts maintain a “Moderate Buy” consensus with an average price target of $21.00; the company also declared a quarterly dividend of $0.0875 per share.

The Chemours Company (NYSE:CC - Get Free Report) CFO Shane Hostetter bought 3,350 shares of Chemours stock in a transaction dated Thursday, August 6th. The stock was acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the transaction, the chief financial officer owned 102,698 shares of the company's stock, valued at $1,534,308.12. This trade represents a 3.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Chemours Price Performance

Shares of NYSE CC traded down $1.23 during midday trading on Monday, reaching $14.52. The company's stock had a trading volume of 4,743,587 shares, compared to its average volume of 3,099,398. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The company has a market cap of $2.19 billion, a P/E ratio of -7.60 and a beta of 1.43. The business's 50 day moving average price is $19.23 and its two-hundred day moving average price is $20.06. The Chemours Company has a fifty-two week low of $10.44 and a fifty-two week high of $28.67.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.07). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business's revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.54) earnings per share. On average, analysts forecast that The Chemours Company will post 0.91 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.0875 per share. The ex-dividend date is Friday, August 14th. This represents a $0.35 annualized dividend and a yield of 2.4%. Chemours's dividend payout ratio is presently -18.32%.

Institutional Trading of Chemours

A number of hedge funds have recently made changes to their positions in the company. Atlas Capital Advisors Inc. acquired a new stake in Chemours during the 4th quarter worth approximately $26,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Chemours during the fourth quarter worth $28,000. Covestor Ltd grew its stake in shares of Chemours by 204.7% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company's stock worth $31,000 after purchasing an additional 1,748 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in Chemours in the fourth quarter valued at $31,000. Finally, Rothschild Investment LLC lifted its holdings in Chemours by 87.0% during the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company's stock worth $32,000 after buying an additional 1,255 shares during the period. 76.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on CC shares. Royal Bank Of Canada dropped their price objective on Chemours from $26.00 to $22.00 and set an "outperform" rating for the company in a research report on Thursday. JPMorgan Chase & Co. increased their target price on shares of Chemours from $17.00 to $22.00 and gave the stock a "neutral" rating in a report on Thursday, May 21st. Truist Financial reduced their price target on shares of Chemours from $30.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday. Weiss Ratings lowered shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday. Finally, Morgan Stanley set a $18.00 price objective on shares of Chemours in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Chemours has an average rating of "Moderate Buy" and an average target price of $21.00.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source